Drug Trial Radar · NCT03283878
Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,770
Actual
Start
Oct 24, 2017
Primary completion
Nov 20, 2024
Study completion Aug 22, 2025
Sponsor
- Lead sponsor
- Duke UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- American Association of Hip and Knee Surgeons; Orthopedic Research and Education Foundation
- First posted
- Sep 14, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty (TKA): Multi-Center Trial is a study that will compare the effectiveness of various perioperative strategies for antibiotic delivery as prophylaxis for periprosthetic joint infections (PJI) and surgical site infection in elective primary TKA. The investigators hypothesize that a single dose of prophylactic antibiotic administered within 60 minutes before the incision is not an effective way to prevent PJI in elective primary total knee arthroplasty (TKA). The investigators also hypothesize that the prolonged delivery (24 hours) of antibiotic prophylaxis after surgery does not further reduce the incidence of PJI in elective primary TKA. Duke University is the only site recruiting both primary total knee arthroplasty and unilateral knee arthroplasty.
Conditions
- Arthropathy of Knee
- Antibiotic Prophylaxis
Interventions
CefazolinDrug
Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA for Group 1. Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA. In addition, two weight based doses of cefazolin will be administered within 24 hours postoperatively for Group 2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Periprosthetic Infection (PJI) as Measured by Chart ReviewTime frame: up to 90 days post-operative
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
University of California, San Francisco
San Francisco, California
Emory University
Atlanta, Georgia
University of Maryland St. Joseph Medical Center & Orthopedic Associates
Towson, Maryland
University Of Mississippi Medical Center
Jackson, Mississippi
Mississippi Bone and Joint Clinic
Starkville, Mississippi
University Orthopaedic Associates, LLC
Somerset, New Jersey
NYU School of Medicine
New York, New York
Duke University Medical Center
Durham, North Carolina
Cleveland Clinic
Cleveland, Ohio
Ohio State University
Columbus, Ohio
Rothman Institute
Philadelphia, Pennsylvania
University of South Carolina
Columbia, South Carolina
BaylorScott&White Research Institute
Temple, Texas
Augusta Health
Fishersville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.